KineMed/Merck Sign Cardiovascular Research Collaboration Pact Potentially Worth $75.5 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
KineMed will use its proprietary reverse cholesterol transport technology to evaluate up to 10 investigational compounds provided by Merck.
You may also be interested in...
Avanir Restructures After Ending Deals With Novartis, AstraZeneca
Plan to reduce operating expenses by $20 million will include some headcount reductions, CEO Katkin tells “The Pink Sheet” DAILY
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.